First independent programme to track pharma action on AMR.

The AMR Benchmark is a tool for tracking the pharmaceutical industry’s response to AMR. By regularly assessing the level of action, it provides a reality check on progress against AMR.

What we measure

The 2020 AMR Benchmark evaluates how 30 pharmaceutical companies are responding to the global threat of AMR. It has examined company actions relating to medicines and vaccines for bacterial and fungal infections. Find out more about the research scopes.

Learn more

How we measure

The AMR Benchmark evaluates pharmaceutical companies in areas where they have the biggest potential and responsibility to limit antimicrobial resistance, such as R&D and managing manufacturing waste. Find out more about the analytical framework.

Learn more

The research process

The Foundation’s Benchmark research team measures company behaviour using a rigorous process of data-collection, verification, scoring and analysis. Find out more about what these phases involve.

Learn more

How we work with experts

Every two years, the Benchmark methodology is refined based on a targeted review of how stakeholders view pharma’s role in limiting antimicrobial resistance. Find out more about this review and the experts involved.

Learn more

The context

Antimicrobials have revolutionised medical care. However, most will eventually become obsolete as pathogens develop resistance. Read about the situation and how the AMRB Benchmark stimulates pharmaceutical companies to ensure effective antimicrobials remain available.

Learn more

What leaders say

All endorsements

"There have been massive improvements in global health in the past decades, with all major pharmaceutical companies taking action. To close the gaps that remain, a greater diversity of companies must get involved and stay engaged."

Jayasree K. Iyer

Executive Director Access to Medicine Foundation

Learn more

View our detailed overview of each company’s performance

Back to top |